POSA28 Reductions in Migraine and Headache Days After Initiating Fremanezumab for Patients with Migraine and Prior Use of Another Monoclonal Antibody Targeting the CGRP Pathway in a US Real-World Setting

M Driessen,O Patterson-Lomba,F Mu, S Thompson, M Seminerio,K Carr,R Sun,T Totev,E Yim,R Ayyagari, J Cohen

Value in Health（2022）

引用 0|浏览3

暂无评分

摘要

This chart review assessed effectiveness of fremanezumab, a fully-humanized monoclonal antibody (mAb; IgG2Δa) that selectively targets calcitonin-gene-related-peptide (CGRP), for reducing monthly migraine days (MMD) and monthly headache days (MHD) up to 6 months in patients with migraine who had previously discontinued another anti-CGRP pathway mAb.

查看译文

关键词

migraine,headache days,fremanezumab,cgrp pathway,monoclonal antibody,real-world

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要